Clinical Trials Logo

Physiological Effects of Drugs clinical trials

View clinical trials related to Physiological Effects of Drugs.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05615948 Active, not recruiting - Clinical trials for Major Depressive Disorder

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

Start date: December 6, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.

NCT ID: NCT05288166 Active, not recruiting - Prostatic Neoplasms Clinical Trials

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

CYCLONE 3
Start date: April 14, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

NCT ID: NCT05284097 Active, not recruiting - Infections Clinical Trials

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Start date: September 19, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, study evaluating the safety and immunogenicity of the 2-dose vaccination regimen, Ad26.ZEBOV, MVA-BN-Filo, in adults and children originally enrolled in the control arm of the EBOVAC-Salone study

NCT ID: NCT04365101 Active, not recruiting - Pneumonia Clinical Trials

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

CYNKCOVID
Start date: May 13, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

NCT ID: NCT04309084 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Start date: May 12, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.

NCT ID: NCT03776994 Active, not recruiting - Clinical trials for Nervous System Diseases

Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine

VEEV
Start date: July 17, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safety and immunogenicity of non-adjuvanted and adjuvanted monovalent VEE VLP Vaccine in healthy adults (ages 18-50 years) when administered via intramuscular (IM) injection at escalating doses of 2 μg, 10 μg, and 20 μg as a 2-dose primary series (Day 0, Day 28) with a Day 140 booster dose. The secondary objective of the study is to evaluate immunogenicity of the vaccine at the aforementioned time points